Rigel (RIGL) Q2 2026 Earnings Report

The call presented multiple meaningful commercial and pipeline achievements—most notably the in‑license and imminent launch of VEPPANU with strong phase III efficacy, ongoing commercial revenue growth (14% product sales growth, record TAVALISSE quarter, 27% REZLIDHIA growth), and promising early R289 data with regulatory incentives. These positives are tempered by lower year‑over‑year net income (partly due to one‑time prior‑year items), a substantial decline in cash reserves (~38.5%), higher operating expenses (+~35.7%), modest decline in GAVRETO sales, and significant upfront/milestone/royalty obligations tied to VEPPANU that may pressure margins and cash flow. Overall, the company communicated confident launch readiness and an optimistic strategic trajectory but with near‑term financial and execution risks to monitor.

Rigel reiterated 2026 financial guidance of approximately $285–$295 million in total revenues, driven by net product sales (excluding VEPPANU) of about $255–$265 million and roughly $30 million in contract revenues, and said it expects reported positive net income for the full year while funding development programs; management also highlighted a ~35% CAGR since 2022 using the midpoint of 2026 net product sales (ex‑VEPPANU). Operational timing metrics included commercial availability of VEPPANU in mid‑August (no standalone sales guidance yet), completion of R289 dose‑expansion enrollment and selection of a recommended Phase II dose in H2 with topline dose‑expansion data expected by year‑end, and Q2 cash and short‑term investments of $95.3 million. Q2 results referenced as context were $67.0 million in net product sales (TAVALISSE $47.4M, GAVRETO $10.7M, REZLIDHIA $8.9M), $11.7M collaboration revenues and $78.7M total revenues, with Q2 net income of $17.3M and total costs and expenses of $55.1M. Transaction terms for VEPPANU cited a $70M upfront payment, $15M transition milestones, up to $320M in potential regulatory/commercial payments, tiered royalties in the mid‑teens to mid‑20s, and Rigel’s commitment to contribute up to $40M over four years to ongoing development.